Arecor Therapeutics CEO on FY25 highlights and progress with AT278 and GLP-1 programmes
13 April 2026
Arecor talks to Biotech TV
23 February 2026
The next leap in diabetes care: a smarter insulin in a smaller pump – Health Awareness
14 November 2025
Proactive Investors interview – Arecor CEO on AT278 partnership with Sequel Med Tech, $11m royalty funding deal and interim result
26 September 2025
Proactive Investors interview – CEO on Skye BioScience partnership and the value of collaborations
22 May 2025
Proactive Investors interview – Strong 2024 progress and 2025 milestones
23 April 2025
Proactive Investors interview – H1 highlights: GLP-1, AT278, and new partnerships
26 September 2024
Proactive Investors interview – Arecor CEO Presents Positive Phase I Trial Results of AT278 at EASD Conference
18 September 2024
Proactive Investors interview – Arecor’s fast-acting insulin shows superior results in diabetes trial
21 May 2024
Proactive Investors interview – Arecor Therapeutics reports strong 2023 results and outlines expanding product pipeline
16 May 2024
Proactive Investors interview – Arecor Therapeutics announces collaboration on oral GLP-1 drug for diabetes and obesity treatment
13 March 2024
Proactive Investors interview – Arecor Therapeutics CEO highlights key 2023 business achievements and future milestones
2 February 2024
Proactive Investors interview – Arecor reveals deal with ‘global medical products company’
5 December 2023
Proactive Investors interview – Arecor Therapeutics takes major step with first commercial sale of AT220
17 November 2023
Proactive Investors interview – Arecor Therapeutics expecting a busy end to the year after solid first half progress
15 September 2023
Proactive Investors interview – Arecor Therapeutics gets second phase 1 trial for AT278 underway
24 May 2023
Proactive Investors interview – Arecor Therapeutics has “a strong basis to accelerate” growth strategy
20 April 2023
Proactive Investors interview – Arecor Therapeutics “confident” in collaboration pipeline after another new deal
14 February 2023
Proactive Investors interview – Arecor Therapeutics “looking forward to another successful year”
19 January 2023
Proactive Investors interview – Arecor Therapeutics’ scientist hopeful that artificial pancreas “edging closer”
15 November 2022
Proactive Investors interview – Arecor’s study shows rapid-acting insulin could enable artificial pancreas system
12 October 2022
Proactive Investors interview – CEO talks through interims, clinical trials and growing momentum
9 September 2022
Proactive Investors interview – Tetris Pharma acquisition plans and focus on key product Ogluo
5 August 2022
Arecor’s Howell says collaborations with top pharmas validate the value of its technology | AIM:AREC
20 June 2022